Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Drugs targeting 5-hydroxytryptamine receptors in acute treatments of migraine attacks. A review of new drugs and new administration forms of established drugs

Research output: Contribution to journalReviewResearchpeer-review

  1. Will novel oral formulations change the management of inflammatory bowel disease?

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Mometasone furoate nasal spray for the treatment of asthma

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Lixisenatide for type 2 diabetes mellitus

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Serotonin 2A receptor antagonists for treatment of schizophrenia

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Inhibition of dipeptidyl peptidase 4 by BI-1356, a new drug for the treatment of beta-cell failure in type 2 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Opening of ATP sensitive potassium channels causes migraine attacks with aura

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Symptomatic migraine: A systematic review to establish a clinically important diagnostic entity

    Research output: Contribution to journalReviewResearchpeer-review

  3. Can tendon reflexes be elicited by both stretch and vibration in man?

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Glutamate levels and perfusion in pons during migraine attacks: A 3T MRI study using proton spectroscopy and arterial spin labeling

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Onset of action in placebo-controlled migraine attacks trials: A literature review and recommendation

    Research output: Contribution to journalReviewResearchpeer-review

View graph of relations
Introduction: The development of sumatriptan, more than 20 years ago, added substantially to the characterization of 5-hydroxytryptamine (5-HT) receptors and their relevance to acute migraine therapy. Recently, 5-HT1F receptor agonists, with no vascular effects, have shown efficacy in the treatment of migraines. Areas covered: This evaluation reviews the recent advances in acute migraine therapy targeting the 5-HT receptor. Specifically, the authors review the pharmacokinetics, pharmacodynamics, clinical efficacy and safety of 5-HT1F receptor agonists and new formulations of sumatriptan and dihydroergotamine (DHE). Expert opinion: Lasmiditan, a non-vascular acting 5-HT1F receptor agonist, is effective in migraine but causes central nervous system-related adverse events, which may considerably limit its clinical use. The efficacy of transdermal sumatriptan is too low for general use in migraine. Intranasal sumatriptan powder could be a step forward compared with oral sumatriptan, but comparative trials are needed. Orally inhaled DHE has a very quick systemic absorption but the onset of effect in migraine is relatively slow with a maximum effect after 2 h. In contrast, orally inhaled DHE results in a low incidence of recurrence. None of these reviewed treatments are likely to fulfill patients' expectations, and the advancement of acute migraine drugs should likely depend on different mechanisms from current 5-HT-related drugs.
Original languageEnglish
JournalExpert Opinion on Investigational Drugs
Volume23
Issue number3
Pages (from-to)375-385
Number of pages10
ISSN1354-3784
DOIs
Publication statusPublished - Mar 2014

ID: 42437327